Contract Pharma Manufacturing News
-
Alkermes plc Completes Sale Of Athlone, Ireland Facility To Novo Nordisk
5/2/2024
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
-
ProPharma And PBL Launch Innovative Cell & Gene Therapy Manufacturing Device
5/2/2024
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today announced that in partnership with PBL, it developed an enclosed, fully automated cell factory device, the Cell Factory Box (CF Box).
-
PCI Pharma Services Begins Installation Of Sterile Fill-Finish And Lyophilization Line As Part Of $100M New Facility Expansion
5/2/2024
PCI Pharma Services, (“PCI”) a world leading global contract development and manufacturing organization (CDMO), has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus.
-
Innovation In Generics: Increased Efficiency Through Peptide API Synthesis Expertise
5/2/2024
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of Gonadotropin-releasing hormone (GnRH) analogues
-
Astellas And Poseida Therapeutics Enter Into Research Collaboration And License Agreement To Develop Novel Allogeneic Cell Therapies In Oncology
5/1/2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
-
Adare Expands Global High Potency Handling & Packaging Capabilities
5/1/2024
Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, today announced expansions of its high potency handling capabilities in the United States and Europe.
-
AbbVie Reinforces Commitment To Science And Innovation With A €150M Euro Investment In New Cutting-Edge Research And Development Facility In Germany
4/30/2024
AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150M in its second largest R&D location worldwide.
-
Phosphorex And NOF CORPORATION Collaborate To Supply Lipid Nanoparticle Formulations Using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series
4/30/2024
Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
-
Cytiva Introduces New Cell Lines To Meet The Challenges And Increasing Demand Of Viral Vector Manufacturing
4/30/2024
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and limited accessibility for patients. Global life sciences leader, Cytiva, is bringing solutions to these challenges with its new ELEVECTA cell lines.
-
INCOG BioPharma Services Continues Positive Momentum
4/30/2024
INCOG BioPharma Services proudly announces that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product.